- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06831552
Uma avaliação randomizada do estudo de fase II da adição da intervenção de recursos para apoiar a equidade (ASSE) a cuidados de apoio usuais para crianças com neuroblastoma de alto risco recentemente diagnosticado (RISE in HR NBL)
The goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (Pediatric Resource Intervention to Support Equity [Pediatric RISE]) to usual supportive care for low-income children with high-risk neuroblastoma can improve parent- and child-centered outcomes.
Participants will be randomized to receive one of the following for 6-months:
- Usual supportive care alone or
- Usual supportive care plus Pediatric RISE
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a randomized Phase II trial evaluating the addition of the RISE supportive care equity intervention to usual supportive care for poverty-exposed children participants with newly diagnosed high-risk neuroblastoma. Participants will be randomized into one of two groups: Usual supportive care or Pediatric RISE plus usual supportive care. Randomization means a participant is placed into a study group by chance.
The research study procedures include screening for eligibility, in-person or virtual appointments, and surveys.
Participation in this research study is expected to last for about 6-months.
It is expected that about 84 participants will take part in this research study.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Kira Bona, MD, MPH
- Número de telefone: 617-632-4688
- E-mail: Kira_Bona@dfci.harvard.edu
Locais de estudo
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Recrutamento
- Children's Hospital Colorado
-
Contato:
- Katherine Lind, MD
- E-mail: Katherine.Lind@childrenscolorado.org
-
Contato:
- Navin Pinto, MD
- E-mail: Navin.Pinto@childrenscolorado.org
-
-
Connecticut
-
Hartford, Connecticut, Estados Unidos, 06106
- Recrutamento
- Connecticut Children's Medical Center
-
Contato:
- Andrea Orsey, MD, MSCE
- Número de telefone: 860-545-9630
- E-mail: aorsey@connecticutchildrens.org
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30329
- Recrutamento
- Children's Healthcare of Atlanta
-
Contato:
- Thomas Cash, MD
- Número de telefone: 404-785-1200
- E-mail: william.cash@choa.org
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 03079
- Recrutamento
- Dana-Farber Cancer Institute
-
Contato:
- Kira Bona, MD, MPH
- Número de telefone: 203-464-9417
- E-mail: kira.bona@childrens.harvard.edu
-
-
New York
-
New York, New York, Estados Unidos, 10027
- Recrutamento
- Columbia University Medical Center
-
Contato:
- Melissa Beauchemin, MD
-
Contato:
- Justine Kahn, MD
- E-mail: jk2034@cumc.columbia.edu
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45229
- Recrutamento
- Cincinnati Children's Hospital Medical Center
-
Contato:
- Katherine Somers, MD
- E-mail: katherine.somers@cchmc.org
-
Contato:
- Meera Kotagal, MD
- E-mail: meera.kotagal@cchmc.org
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Recrutamento
- Children's Hospital of Philadelphia
-
Contato:
- Rochelle Bagatell, MD
- Número de telefone: 267-426-9737
- E-mail: bagatellr@chop.edu
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- Recrutamento
- University of Texas Southwestern Medical Center
-
Contato:
- Puja Umaretiya, MD
- Número de telefone: (214) 456-2382
- E-mail: puja.umaretiya@utsouthwestern.edu
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98105
- Recrutamento
- Seattle Children's Hospital
-
Contato:
- Anurekha Hall, MD
- Número de telefone: 206-987-2106
- E-mail: anurekha.hall@seattlechildrens.org
-
Contato:
- Kristine Karvonen, MD
- E-mail: Kristine.Karvonen@seattlechildrens.org
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Patient cohort: The randomized Phase II multi-center RISE intervention will be conducted among a population of poverty-exposed children with high-risk neuroblastoma. Poverty will be a priori defined as parent-reported low-income (<200% Federal Poverty Level). Children receiving treatment for cancer at study sites will serve as the study cohort, with parents/guardians as survey informants and intervention recipients on behalf of their minor children given that parents (not children) typically manage household finances.
- Patient newly diagnosed with high-risk neuroblastoma
- Patient has established care at study site and initiated cancer-directed therapy
- Patient has not yet initiated Induction Cycle 3
- Patient aged 0-17 years at the time of consent
- Parent/guardian screened positive for self-reported low-income (<200% Federal Poverty) *
- Family primary residence in MA, PA, IL, CA, WA, CT, GA, WI and OH
- Both patients co-enrolled on ANBL2131 or those receiving standard of care therapy at their center are eligible to participate
- Patients of all languages are eligible to participate
Exclusion Criteria:
- Foreign national family receiving care as an Embassy-pay patient.
- Child or household member receiving SSI
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Arm 1: RISE Intervention + Usual Supportive Care
Participants will be randomized in a 1:1 ratio and stratified according to treatment group and Household Material Hardship (HMH) severity score. Participant parents/guardians will complete:
|
Income-poverty targeted, supportive care intervention that includes direct cash transfers delivered by the Fund for Guaranteed Income, a non-profit organization, along with benefits counseling to discuss the risk of means-tested benefits loss or reduction. Funds will be dispersed to families via debit card or through personal banking, PayPal, or Venmo on a twice monthly basis for a total of twelve disbursements (6-months). Meetings with a benefits counselor will be conducted by the HIPAA-compliant video conference platform, Zoom.
Outros nomes:
|
|
Sem intervenção: Arm 2: Usual Supportive Care
Participants will be randomized in a 1:1 ratio and stratified according to treatment group and HMH severity score. Participant parents/guardians will complete:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Household Material Hardship (HMH) Score Reduction Rate
Prazo: Baseline (T1) and 6-months (end-intervention; T3)
|
HMH score reduction rate is defined as the proportion of patients achieving at least 1 domain reduction in (food, housing, utility or transportation insecurity). HMH scores range from 0 to 4, with scores of 0 indicating no hardship (unexposed) and scores of 1-4 indicating the presence of hardship (exposed). Patients who are unexposed to HMH at baseline (HMH score of 0) are excluded from the analysis. |
Baseline (T1) and 6-months (end-intervention; T3)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pediatric-Modified Comprehensive Score for Financial Toxicity (COST)
Prazo: 3-months (end-of-induction; T2) and 6-months (end-intervention; T3)
|
Financial toxicity will be assessed with the 12-item modified COST measure. Each item is rated on a 0-4 scale, yielding a total score range of 0-48, with higher scores indicating better financial well-being. The final COST score will be calculated per established methods. A change of approximately 5 points is considered a minimally important difference (MID), representing a clinically meaningful change in financial toxicity. |
3-months (end-of-induction; T2) and 6-months (end-intervention; T3)
|
|
Parent Psychological Distress (Kessler-6) Score Change from Baseline to 6 Months
Prazo: Baseline (T1) and 6-months (end-intervention; T3)
|
Psychological distress will be assessed using the 6-item Kessler-6 scale. The scale includes 6 items scored from 0 ('none of the time') to 4 ('all of the time'), yielding a total score ranging from 0 to 24, with higher scores indicating greater psychological distress. A reduction in scores of approximately 2.8 points is considered a minimally important difference (MID), representing a clinically meaningful improvement in psychological distress. |
Baseline (T1) and 6-months (end-intervention; T3)
|
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive Abilities Score Change from Baseline to 6 Months
Prazo: Baseline (T1) and 6-months (end-intervention; T3)
|
The PROMIS Applied Cognition-Abilities short form is an 8-item measure assessing subjective learning and memory, attention and concentration, executive function, and processing speed. Responses are scored on a scale of 1-5, and the total score is converted to a T-score with a mean of 50 and a standard deviation (SD) fixed at 10. Higher scores suggest better perceived cognitive function. |
Baseline (T1) and 6-months (end-intervention; T3)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Kira Bona, MD, MPH, Dana-Farber Cancer Institute
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Neoplasias
- Neoplasias por Tipo Histológico
- Neoplasias Glandulares e Epiteliais
- Neoplasias Neuroepiteliais
- Tumores Neuroectodérmicos
- Neoplasias, Células Germinativas e Embrionárias
- Neoplasias, Tecido Nervoso
- Tumores Neuroectodérmicos Primitivos Periféricos
- Tumores Neuroectodérmicos Primitivos
- Neuroblastoma
Outros números de identificação do estudo
- 24-600
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Dr. Kira Bona. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Prazo de Compartilhamento de IPD
Data can be shared no earlier than 1 year following the date of publication
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .